Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Cyclo 3 (commonly marketed as Cyclo 3 Fort) is a well-established venotonic and vasculoprotective combination drug developed by Pierre Fabre. It consists of three active ingredients: a dry extract of butcher's broom (*Ruscus aculeatus*), hesperidin methyl chalcone, and ascorbic acid (Vitamin C). The combination is widely used for the symptomatic treatment of chronic venous insufficiency (including heavy legs, pain, and nocturnal cramps), hemorrhoidal crises, and certain types of gynecological bleeding (such as metrorrhagia associated with intrauterine devices or microprogestogen contraception). *Ruscus aculeatus* extract acts as an agonist of postsynaptic alpha-adrenergic receptors, promoting venoconstriction and improving venous tone. Hesperidin methyl chalcone, a flavonoid, reduces capillary permeability and increases capillary resistance, while ascorbic acid protects capillary walls and supports collagen synthesis.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Cyclo 3.